Introduction: Cardiac #amyloidosis is an underdiagnosed cause of heart failure characterized by extracellular deposition of misfolded proteins, most commonly transthyretin (ATTR) or immunoglobulin light chains (AL). Despite recent advances in disease-modifying therapies, prognosis remains poor. Sodium-glucose cotransporter 2 inhibitors ( #SGLT2i ) have demonstrated cardiovascular and renal benefits. However, evidence regarding their safety and efficacy… Continue reading Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review
2 Medical News 